{
    "Page_1": "AMD A-to-OCT-to-Rl-to-Z\nWhatYou Need toKnow\nGreg Caldwell, OD, FAAO\nNorthern Rockies Optometric Conference\nJuly 16,2021",
    "Page_2": "Disclosures- Greg Caldwell, OD, FAAO\n6~ The content of this activity was prepared independently by me - Dr. Caldwell\nG~ Lectured for: Alcon, Allergan, Aerie, BioTissue, Kala, Maculogix, Optovue,\nG~Advisory Board: Allergan, Sun, Alcon, Maculogix, Dompe\nG^ Envolve: PA Medical Director, Credential Committee\nG~ Healthcare Registries - Chairman of Advisory Council\n6~I have no direct financial or proprietary interest in any companies, products or services\nmentioned in this presentation - scanner owner, Macologix, Optovue OcT\nG~ The content and format of this course is presented without commercial bias and does not claim\nsuperiority of any commercial product or service\nG~ Optometric Education Consultants - Scottsdale, Minneapolis, Florida (Ponte Verda Beach)\nMackinac Island, Ml, Nashville, and Quebec City - Owner\nOptometric\nEducatior\nConsultants",
    "Page_3": "Course Description and Objectives\nThis course will evaluate Age Related-Macular Degeneration (AMD) from subclinical to advanced\nAMD. It will emphasize structure (OCT) and function (dark adaptation) testing to provide early\ndetection and proper staging of AMD. Once accurately diagnosed the course will discuss\napplying current clinical guidelines in the treatment of subclinical to advanced AMD. The course\nwill also call attention to OCT structural changes indicating progression.\nCourse Objectives:\nG~ Show how to diagnose the often missed subclinical or early AMD\n6~ Increase ones understanding on function testing for AMD\nG~ Increase ones understanding on the structure changes to properly stage AMD\nG~ Show how to treat subclinical or early AMD\nG~ Discuss OCT Angiography utilization in AMD\nG~ Review treatments for Intermediate AMD\nG~ Review treatments for exudative/choroidal neovascular AMD",
    "Page_4": "AMD Dominance\n6~ In 2010, the World Health Organization estimated that 5% of the world's blindness was due to\nAMD\n6~ Leading cause of blindness over 55-year-old in USA\nG~11 million people in USA have AMD, 22 million by 2050\n★ Approximately 1 in 14 people over the age of 40 has some degree of macular degeneration\n* Over 60, 1 in 8 (12.5%)\n* Over 80, 1in 3 (33 %)\n6~ More cases of AMD than Alzheimer's, breast cancer, and Parkinson's combined\n6~ The leading cause of blindness and vision loss in Caucasians\nG~ Affect 1 in 5 families\nG~ Hereditary strongest genetic linkage of any major diseases",
    "Page_5": "Eye Care Professional Landscape\nG~58,000 eye care professionals\n*40,000 optometrists\n*18,000 ophthalmologists\n About 10% are retinal specialists",
    "Page_6": "Age-Related Macular Degeneration is the\nLeading Cause of Preventable Blindness in the Western World\nClinical AMD is more prevalent than Glaucoma and Diabetic Retinopathy combined\nS\nCNV PATIENT OUTCOMES ON 1ST\nPREVALENCEOFMAJOREYEDISEASES (US)\nPRESENTATIONFORAnti-VEGFTREATMENT\n16.0\n100%\n14M\n14.0\n78%\n80%\n12.0\n3-5X\nLegally\n10.0\n60%\nBlind in\nOne Eye\n(millions of people)\n8.0\n40%\n6.0\n4.9M\nVisually\n22%\n4.0\n2.7M\n20 %\nImpaired\n(< 20/50)\n2.0\nin One Eye\n0%\nGlaucoma\nPoor\nDiabetic\nAMD\nGood\nRetinopathy\nReferences: https://www.aao.org/newsroom/eye-health-statistics | Neely D, et al. Ophthalmol. Published online April 27, 2017.I Klein R, et al. Arch Ophthalmology. 2011;129(1):75-80. 1",
    "Page_7": "Primary Eye Care is Missing Visible Disease\nin 25% of Patients Using Standard Workup\nJAMAOphthalmology|OriginalInvestigation\n1288 eyes from 644 people\nPrevalenceofUndiagnosedAge-Related\n. Mean age of 69.4\nMacularDegenerationinPrimaryEyeCare\n. 36% male\nDavidC.Neely,MD;KevinJ.Bray,MD;CarrieE.Huisingh,MPH;MarkE.Clark,BS;\nGeraldMcGwinJr,PhD;CynthiaOwsley,PhD\nDoctors were aware that they were\nrecruiting patients for an AMD study!!!\nistetWithAMD\nV 30% of missed AMD eyes had large drusen (lntermediate AMD)\nV Well-known risk factor for progression to advance disease\nODsandMDsmissAMDdiagnosisequally\nReference: Neely DC, Bray KJ, Huisingh CE, Clark ME, McGwin G, Owsley C. Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care. JAMA\nOphthalmol. 2017;135(6):570-575.",
    "Page_8": "AMD Considerations and Pearls\nG~ There is currently no cure for AMD\n* Proper detection and care many prevent significant visual acuity loss in many patients\nG~ Are anti-VEGF injections our patients' best hope?\nG Late-stage treatments, albeit are necessary, they have little impact on central acuity\n★ Impacting our ability to intervene in in early to intermediate AMD?",
    "Page_9": "Optometrists and All Eye Care Professionals Responsibility\n6~Rethink our responsibility related AMD diagnosis and management\nG^Commit to that we will do better in\n* Early detection\n* Treatment\n6~Know, execute, and employ current clinically appropriate Practice Guidelines\n* Those that preserve vision\n★ Don't wait until vision has been lost\nG~Closely monitor and treat the early detected disease\n* If progresses to advanced AMD, better opportunity to save vision",
    "Page_10": "foDsonFacebook\nODs on Facebook\nemer18at5:10 PM\nNVITEMEMBERS\nLossof foveal pitwithmacular tractionanddruse\nncewhich\nmay bevitellform.AmslernormalOUVAOD20/25-,OS20/30+Mld\n9,870M\nf\ncataracts ou.Who sends to retina?who monitors?Options?\nAbout\nODs on Facebook\nLike-Reply-20\nDiscussion\nX\nTracy Kimmelman Casten Mon\nategroup\nLike:Rep2d\nmunityiRIVATEOOsstnt\nAbout\nCibele SSapritManior\nMembers\nDiscussior\nLikaRaply-2d\nGROUPTYPE\nEvents\nSocial Learning\n证\nVideos\nMembers\nPhotos\nREATENEW GROUPS\nEvents\nDr.AlanGlazierMon\nVideos\nL.ike-Repy2a\nFiles\nThica\nfamilyand teammates.\nPhotos\nNick Waber Monitor\nFles\nWatchParty\nSee.All\nRecommendations\nAzadoh Razmandi Monito\nLike-Repy2d\nSearch this group\n1stAnnualOc\nWatch Party\nutucs InCancunCE\nTherapeut\nAviAlboher\n11\nSearch this group\ntamiyandtoommates\nOCTConnect\nnMexico\nCreated forODs\nFacabooe\nesInCan\nODs on Facebook\n000\nDrs.Center, Imler,Gjuri.\ning2020\nMedical Optomety Am..\n1\nCME40D\nLike\ncomr\nCME40D\nSteelars Nation\nJamesFaneillin\nBrlan Gerlach Monitor\nOptometrists of Am\nFocebooik\nCpt\nLikeReply2d\nPOAODson\nX\nTracy Kimmelman Casten Monit\nLike-Reply-2d\nSawfordFamilyEvents\n福\nCibole S.Saporito Monitor\nLik-Aeply-2d\nMa\nAmsleranng\nManaged Mediceid In P.\nEyerls O0's\nLike-Reply2d\nSteve Burnham whatsretina going todo\nEyenis CD's\nLkeRepiy2d\nDavis\nEnglish(US)-Eupa\nDr.Alan GlazierMonior q3\nBs(Brasil]-Francais（France)\nDeutsch\nLike-Reply-2d\nNickWeber Monito\nLike-Reply-2d\nFacebook2019",
    "Page_11": "Early Onset Pathogenesis\n6^ Drusen small or large are not makers for early stage AMD\n★ Visible structural evidence of a pathological process\n Underway for quite some time\nG^ Cholesterol deposits exist beneath the surface long before drusen form\n★ Cannot be seen with structure-based methods\n★ Cholesterol produced by RPE and deposits into Bruch's membrane\n* Continue to layer in Bruch's membrane\nG^ As this cholesterol accumulates the process unfolds with compromise to the outer retina\n* Inflammation\n* Oxidative stress\n★ Disruption of oxygen and nutrients\n* Drusen formation\nG~ Impaired Vitamin A across Bruch's membrane\n★ Functional impairment can occur to dark adaptation",
    "Page_12": "Healthy choriocapillaris, Bruch's, RPE, and Photoreceptors",
    "Page_13": "Cholesterol barrier deposited along Bruch's and RPE",
    "Page_14": "RPE Secretes even more cholesterol and degenerates",
    "Page_15": "Finally, visibly evident drusen on fundus evaluation",
    "Page_16": "AMD is a Disease Process that Starts Below the Surface\nDRUSENFORMATION",
    "Page_17": "Staging of Drusen\nWhat method to detect?\nGSubclinical or sub-structural - cholesterol layer\nFunctional\nG~Small drusen < 63 microns\nExam, photos, SD-OCT\nG~Medium drusen > 63 - <125 microns\nExam, photos, SD-OCT\nG~Large drusen > 125 microns\nExam, photos, SD-OCT",
    "Page_18": "Beckmann Committee Classification of AMD\nG~Based on presence of lesions within 2 DD of fovea in either eye\n* No AMD\n None or few small drusen, < 63 microns\n No AMD pigmentary abnormalities\n*EarlyAMD\n Medium drusen, > 63 - <125 microns\n No AMD pigmentary changes\n* Intermediate AMD\n 1large drusen, > 125 microns\n Any AMD pigmentary changes\n* Advanced AMD\n Any geographic atrophy\n Choroidal neovascularization (CNV)",
    "Page_19": "Measure the Drusen with Your OCT\nMShov Boundary Curve\nAutoZoom\nPrin\nChangc Sclcction\nChangc Analysis\noURcport",
    "Page_20": "Measure the Drusen with Your OCT\nLeft/",
    "Page_21": "Measure the Drusen with Your OCT",
    "Page_22": "Choroidal Neovascularization (CNV)\n6~Type 1 - Occult\nG~Type 2- Classic\n6~Type 3- RAP\n6~Type 4- Mixed",
    "Page_23": "Predictors of Progressing to Advance Disease\nG~Hyper-reflective foci\nG~Vision loss from geographic or\nG~Reticular pseudodrusen\nexudative/CNV\nGNascent geographic atrophy\nG~Sub-RPE hyper-reflective columns\nG~Drusen substructures\nG~Drusen load and regression",
    "Page_24": "Tools for Diagnosis, Management, and Treatment of AMD\nG^Comprehensive eye exam - structural, some functional\n6~Fundus photography and FAF - structural\nG~OCT and OCT Angiography - structural\nG~Dark adaptation - functional\nG~How about macula pigment density testing",
    "Page_25": "Applying a Familiar Standard of Care:\nTwo Multifactorial Diseases\nGlaucoma\nAMD\nStructure\nCup-to-disc\nDrusen\nRatio\nFunction\nVisual Field\nDarkAdaptation\nIntraocular Pressure (IOP)\nAge\nRisk\nCorneal Thickness\nGenetic Testing\nAge/race\nHealth and Lifestyle (Smoking)\nFamily history/etc.\nMacular Pigment Optical Density (MPOD)\nHealth and Lifestyle (Diabetes)\nContrast Sensitivity.",
    "Page_26": "Dark Adaptation in AMD\nFunction Test\nG~Measures how long to recover from bright light to darkness\n★ Rod intercept line (Rl) time\nG~Functional test that can help overcome the challenges in diagnosing AMD\nG~Alabama Study on Early Are-Related Degeneration (ALSTAR)\n★ Able to detect subclinical 3 years before clinically visible\n* 325 adults without clinically detectable AMD\nG~Rod deterioration happens in earliest stages of AMD\n* Earlier defection before visual acuity\nG~AdaptDx 92284\n* Sensitivity 90.6%\n* Specificity 90.5%",
    "Page_27": "3:274\nQ Search\n宣\nwrite a post\nMarkKetcham.1st\nofSales and Con\n59m.\nMacuLogix-TheAMD Experts\n+Follow\n3h.@\nMeet thenewestmemberofourt\nAndjustintimeforthe\nNewYear!\nOurfriendlyon-board technician,Theia,guidespatients\nDark Adaptation in AMD\nthroughthenew,revolutionaryAdaptDxProdark\nadaptatontstweredbyartificiaintlligenceh\ndeliversa uniform experience,every time.er\npersonalizedcoachingensuresconsistentrelable\nresults.#AMDExperts\nFunction Test\nStay tuned formore details about the #AdaptDxPro!\n#NewYear2020\nJanuary 1st, 2020\n#NewYear #eyecare #eyehealth #darkadaptation\n#preventblindness\nQo1\nA5\n白\nMyNetwor\nPost\nNotifications\nJobs",
    "Page_28": "AdaptDx Pro Now Available for Clinical Use\nHandheld Controller\nwith Rechargeable Battery\nand USB-C Cable\ndaptb\nDiopter Adjustments\nLCD Display",
    "Page_29": "This Means We Now Have an Early Symptom\nWe Can Use to Help Diagnose AMD\nNo AMD\nNight vision impacted in early AMD: 3O+ studies\nAMD patients often give up driving at night\nNight vision is impaired before day vision\nTypically ECP's chalk this complaint up to\nNormal night vision\ncataracts\nSubclinical to Early AMD\nAskEveryPatientOver50\nAboutTheir NightVision\nImpaired night vision",
    "Page_30": "OCT in AMD\n6Need spectral domain to follow intermediate or worse AMD\nG~Able to identify OCT predictors of progression\nEspecially in identifying OCT predictors of progression\n* Hyper-reflective foci\n* Reticular pseudodrusen\n* Nascent geographic atrophy\n* Sub-RPE hyper-reflective columns\n* Drusen substructures\n* Drusen load and regression",
    "Page_31": "Hypo versus Hyper Reflectance",
    "Page_32": "Can We Learn From These Pictures?",
    "Page_33": "Can We Learn From These Pictures?\nGallitzin",
    "Page_34": "Hypo versus Hyper Reflectance\nRaster\nRight/ OD",
    "Page_35": "Case 1 - OCT Predictors of Progression\nHD Angio Retina\nScan Quality7/10\nRight/ OD\nExportAngio\n30Diepiay\nOverVue\nEditBnd\nQuickVue\nRetn\npser-un",
    "Page_36": "Case 1 - OCT Predictors of Progression\nHDAngioRetina\nScanQuality7/10\nRight/ OD\nExport Angio\n]u5.009x009\n30 bepay\nEditBnd",
    "Page_37": "Case 1 - OCT Predictors of Progression\nHD Angio Retina\nScan Quality 8/10\nLeft/Os\nExportAngo\nix\n30Dispiay\nverVue\nEditBn\nQuickVue\nsucesibo",
    "Page_38": "Case 2 - OcT Predictors of Progression\nHD Angio Retina\nRight / OD\nScan Quality8/10\nExpurtArgo\n00x6.00Scan Size（m）\n30Dispey\noff\nO\nEditBnd\nper-\nffeetiun",
    "Page_39": "Case 2 - OcT Predictors of Progression\nGrid\nLeft/ OS\nSignalStrengthiIndex\nC1x1\n1x2\nC2x2\nAuto Zo\n6.00x2.00Scan Size(mm",
    "Page_40": "Case 2 - OcT Predictors of Progression\nHDAngioRetina\nScanQuality5/10\nLeft/Os\n6.00x6.00ScanSize(m)\n30Displey\nDverVue\nEditBne\nQuickvue",
    "Page_41": "Case 3 - OcT Predictors of Progression\nHD Angio Retina\nRight/OD\nScanQuality8/10\nax\n3DDisplay\nDverVue\nQuickvue\nShond\nfet(ua",
    "Page_42": "Case 4 - OCT Predictors of Progression\nHD AngioRetina\nScan Quality 5/10\nLeft/Os\n6.00x6.0Scan Size(mm）\n30 Display\nQuickvue\nPlay",
    "Page_43": "Case 5 - OcT Predictors of Progression\nGrid\nRight / OD\nSignal Strengthiiciex\n1x1\n1x2\nC2×2\nAtoZ0m\n6.00x2.00 ScanSize(mm]",
    "Page_44": "Case 5 - OcT Predictors of Progression\nGrid\n Right / OD\nSignalStrength lndex\n1x1\n1x2\nC2x2\nAutoZoon]\n6.002.00ScanSize（mm）",
    "Page_45": "Case 5 - OcT Predictors of Progression\nGrid\nSignel Stren gh index\nLeft/Os\nx2",
    "Page_46": "OCT Angiography in AMD\nStructure Test\nG~Able toidentify occult or classic CNV before they leak\nG~Non-invasive technique\nG~Subclinical CNV or“Occult non-exudative CNV\"\n* Risk of exudation at 12 months is 15.2 times greater compared to eyes without subclinical\nCNV",
    "Page_47": "OCT Angiography\nA New Approach to Protecting Vision\nNon-invasive visualization of individual layers of retinal vasculature\n Pathology not obscured by fluorescein staining or pooling\nImage acquisition requires less time than a dye-based procedure\n> Reduced patient burden allows more frequent imaging to better follow disease\nprogression and treatment response\nFAofCNV\nOCTAofCNV",
    "Page_48": "Enface OCT-A Slabs\nBased on Retinal Anatomy\nOuter Retinal Zone (ONL - BM)\nEn Face Visualization of Layers\nBased on Retinal Anatomy",
    "Page_49": "Normal Retinal Vasculature\nSuperficial Capillary Plexus\nDeep Capillary Plexus\nOuter Retina\nChoriocapillaris\n3um Below ILM → 15 μm\n15um Below ILM → 70 μm\n70μm Below IPL → 30 μm \n30 μm Below RPE Reference → 60 μm\nBelowIPL\nBelowIPL\nBelowRPE Reference\nBelow RPE Reference",
    "Page_50": "Type 1“Occult\"(\nCNV\nRPE\nOccult non-exudative CNV\nChoroid\nNew vessels develop in the choroid\nNew vessels located below RPE and above Bruch's membrane",
    "Page_51": "Type 1“Occult\" CNV\n6~ New vessels develop in the choroid\n6~ New vessels located BELOW RPE and\nABOVE Bruch's membrane\nRPE\nBruch's\nMembrane\nADn\nChoroid",
    "Page_52": "CNV?\n72y/oHispanicmale\n20/30\nHistoryof“DryAMD",
    "Page_53": "Multimodal imaging and OCTA\nVAGUE???\nVascularized\nNon-vascularized",
    "Page_54": "Type 1 CNV:BelowRPE,WiderthanType2,AvascularZoneUsuallyNotInvolved",
    "Page_55": "And the not so obvious ones...",
    "Page_56": "6x6\n3x3",
    "Page_57": "Case example: 70 y/o WM, AMD\nFluoresceinAngiography\nAngio-Superficial\nAngio-Deep\nAngio-Outer Retina\nAngio-Choroid Capillary\nBelow the RPE",
    "Page_58": "Type 2“Classic\" CNV\nuch'sMembrane\nChoroid\nG~ New vessels develop in choroid\n6~ New vessels located above the RPE and above Bruch's membrane",
    "Page_59": "Type 2 “Classic\" CNV\nG~ New vessels develop in choroid\n6~ New vessels located ABOVE the RPE\nand ABOVE Bruch's membrane\nRPE\nBruch's Membrane\nChoroid",
    "Page_60": "Type2 CNV:Above RPE,SmallerthanType 1,AvascularZone Always Involved.\nVeryHeterogeneousShapes",
    "Page_61": "48 y/o WM 2 week history of “dark spot\" OD",
    "Page_62": "Why I Love to Teach\nHD Angio Retina\nScanQuality6/10\nLeft/OS\nExportAngio\n6.00x6.00 Scan Size(mm\nT\nKuei-Yu Chang\nShowLine",
    "Page_63": "Retinal Angiomatous Proliferation\nRETINA\nRPE\nCHOROID\nStage 1\nStage 2\nStage 3\nIntra-retinal\nNeovascularization\nNeovascularization\nproliferation\npenetrates the sub-\npenetrates the\nRPE space\nretinal space\n*Hemes\n*Neurosensory\n*Vascularized PED;\n*Edema\ndetachment\nCNVM\n*Exudate\n*Serous PED",
    "Page_64": "https:/jamanetwork.com/journals/jamaophthalmology/fullarticle/42089",
    "Page_65": "Inspect the SD-OCT carefully!!\nVA20/40\nHYPER-REFLECTIVE lesion above\npigment epithelial detachment\nStage 2\nIntraretinal cysts\nSerous pigment epithelial\ndetachment/ neurosensory\ndetachment",
    "Page_66": "Stage3\nhttp://imagebank.asrs.org/file/26943/retinal-angiomatous-proliferation\nhttps://www-ncbi-nlm-ni-gov.ezproxylocal.ibrary.nova.edu/pubmed/29019795",
    "Page_67": "OCTangiographyder\nWhatabouttheOCTA?\nisoftype\nType 3 CNV: Intraretinal Anastomosis: THROUGH RPE\nInner retina (SCP+DCP) to Outer retina (Avascular/choriocapillaris)",
    "Page_68": "WhatabouttheOCTA?\nleovascularizatior\nType 3 CNV: Retinal/Choroidal Anastomosis: INTO CHOROID\nInner retina (SCP+DCP)to Outer retina (Avascular/choriocapillaris)",
    "Page_69": "Type 4 “Mixed\"- Subretinal and Sub-RPE\nG~Two or more CNV layers\n* One above the RPE, one below the RPE\nG~High flow lesions\nPiucioliZof4",
    "Page_70": "Type4CNV:InitiallyLocatedBelowtheRPE,NVSpreads\nintotheOuterRetina\nAngio-Deep\nAngio-OuterRetina\nAngio-ChoroidCapillary",
    "Page_71": "Green: Type 1 (Sub RPE)\nYellow: Type 2 (Subretinal)",
    "Page_72": "Case Example: Multimodal imaging of 66 y/o Caucasian male\n0:22\n0:40\nFundus image\nFFA: Early; Classic component\nFFA: Late; Classic\nand Occult\nCourtesy of Novais et al.",
    "Page_73": "angioFLow\nChoriocapillaris\nRed: Occult;\nYellow: Classic\nCourtesy of Novais et al.",
    "Page_74": "OcT Angiography\nSubclinical CNV or “Occult non-exudative CNv\"\nRisk of exudation at 12 months is 15.2 times greater\ncompared to eyes without subclinical CNV",
    "Page_75": "HD Angio Retina\nScanQuality3/10\nRight/OD\nExcortAngio\n5.00 ×6.00 Scsn Sire (mm)\nOverVue\nEditBnd\nQuickvue\nOccult\nNon-Exudative\nPlay\npug OuS\nCNV\nNoMCT\nPatient A\nColr\nShowLine",
    "Page_76": "HD Angio Retina\nScan Qualty 3/10\nRight/OD\nExport Angio\n6.00 x 6.00 Scan Size(mm）\nDDapay\nOverVue\nQuickVue\nOccult\nNon-Exudative\nCNV\nShow Bnd\nNo MCT\nPatient A\nColor\nOlfset(um)",
    "Page_77": "HD Angio Retina\nScan Quality 3/10\nRight/ OD\nExportAngo\n5.D0x6.005canSize(mn\n3DDioplay\nO\nOverVue\nEditBnd\nQuickvue\nOccult\nplay\nNon-Exudative\npugmus\nNoMCT\nCNV\nShowLines\nPatient A",
    "Page_78": "Which is More Suspicious?\nHD Angio Retina\nScanQuality7/10\nRight / OD\n6.00 x6.00ScanSize(mm）\n3DDisplay\nO\nOverVue\nEditBn\nQuickVue\nAutoZoom",
    "Page_79": "OCT Angiography Evaluation AMD\nAngio Retina QuickVue\nScanQuality2/10\nRight/ OD\nExt\nPrint\nOverVue\nShowLines\nShowBnd\nAutoZoom\n#\nThickness\nOverla",
    "Page_80": "OCT Angiography Evaluation AMD\nAfter and Before Bevacizumab (Avastin)\nRight/OD",
    "Page_81": "Evaluation AMD Patients for Neovascularization\nOCT Grid\nGrid\nLeft/Os\nSignalStrengthIndex",
    "Page_82": "Evaluation AMD Patients for Neovascularization\nUsing OCT Angiography\nHDAngioRetina\nLeft/Oos",
    "Page_83": "At-risk Patients May Convert to Wet AMD\nat Any Point Between Follow-up Visits\nVisit\nVisit\n1\n2\nConverts\nConverts\nConverts\nafter office\nbetween\nbefore office\nvisit\nofficevisits\nvisit\nMore likely\nLess likely to\nto lose vision\nlosevision\nReference: Rauch R, et al. Retina. 2012:32(7):1260-1264.",
    "Page_84": "Notal Vision -ForeseeHome? product overview\nUsesPreferential\nHyperacuity\nPerimetry (PHP)\n6,000+ actively\ntesting patients\nMedicare\ncovered\nProven efficacy\n600+ active\nwith level 1\nevidence\nprescribers\nReference: Data on File",
    "Page_85": "Readjustingour point ofview topreventablevisionloss\nAREDS\nOn average,those diagnosed at\nDryAMD\nBaseline\ndriving visionmaintainvision\n(CATT1&2yeardota）\n20/25\nWetAMD\n20/32\nOnset\n+11.6/\n+6.6\nPreventable Vision Loss\n2Yaors\nANCHOR/MARNA\n+1:7\nBUT WHEREDID\n4Yoars\nSaving Lines\nHORIZON\nWE START?\n-8.6\n7.3Yaors\n7-UpStudy\nForeseeHome Study Results\nCurrent Standard of Care\n20/32averageVA\n20/83average VA2\n1.ChEYTElly\n+94% 20/40 or better\n13-41%20/40orbefter\n2014;121-535.5442RooP,LumF,WoodK,al\nOphiaogy.2018125[45225283.HAC,AiiTA\nBrowmDM,Boyar DS,RogloCD,Haiar JS.AA\n0.23median discarea size lesions\n2.9-4.2discarea sizelesions3\nOphalol2017;135（3]:268-273.",
    "Page_86": "Notal Vision- PERlMETRY: The ForeseeHome Test\nTotal of 500 data points\ntested 3 to 5 times each\nStimuli are presented\nOptic disk\non screen for 160 ms\nVisual field - central 140\n0.75°\n(4200 microns)\nresolution\nMacula",
    "Page_87": "Once pathology is suspected, the area is\nbracketed to localize and quantify pathology\nWhen a patient clicks on the\n\"pathological distortion,\"\nthe algorithm will present\nOptic disk\nstimuli of various magnitudes\nover the location to determine\nthe size and shape\nMacula\nPathology",
    "Page_88": "CASE 1\n86 y/o Male\nBaseline Vision: 20/30 OU\n(10\nTrend Score\n6/23/17\n9/7/17\n11/5/17\n1/3/18\nSTARTED TESTING\nALERTED\n20/60 OD and asymptomatic",
    "Page_89": "Ocular Genetic Testing",
    "Page_90": "Generalized Ocular Testing\nInherited Retinal Disease and Spark Therapeutics\nPanel tests for mutations in approximately 300 genes associated with\ninherited retinal disease (IRD)\nMore commonly tested for:\nID\n Retinitis pigmentosa\n Leber congenital amaurosis\nStargardt disease\nYOUR\nIRD\nCommonly associated symptoms\nNyctalopia\nCentral and/or peripheral field loss\nINHERITEDRETINALDISEASE\nGENETESTINGINITIATIVE\nColor vision deterioration and/or loss\nSevere photophobia\n**ID your IRD does NOT currently test for genes associated with AMD**",
    "Page_91": "Generalized Ocular Testing\nInherited Retinal Disease and Spark Therapeutics\nIDYOURIRD°TestingPanel\niRD\nyieds",
    "Page_92": "Age-Related Degeneration GeneticTesting\nPeer-ReviewedPublishedStudies\nProspective assessment of genetic effects on progression to different stages of age-related\nmacular degeneration using multistate Markov models. /OVS 53.3 (2012): 1548-1556.\nCFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with\n    -\nValidation of a prediction algorithm for progression to advanced macular degeneration subtypes.\nJAMA ophthalmology 131.4 (2013): 448-455.\nTreatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number\nin the Age-Related Eye Disease Study. Ophthalmology 122.1 (2015): 162-169.\nResponse to AREDS supplements according to genetic factors: survival analysis approach using\nthe eye as the unit of analysis. British Journal of Ophthalmology 100.12 (2016): 1731-1737.\nCFH and ARMS2 genetic risk determines progression to nvAMD after antioxidant and zinc\nsupplementation. Proc National Academy of Sciences 115.4 (2018): E696-E704.",
    "Page_93": "Age-Related Degeneration Testing\nArctic Medical Laboratories (https://arcticdx.com)\nVitaRisk\nPREDICTANDPROTECT\nVita Risk?isaDNA testmeasuring thetwomaingeneticvariations(threegeneticvariationsintwogenes) that\ninteractwithcommonvitamin/mineral supplementscontainingzinc.Peopleinonegeneticgrouphaveincreased\nriskofprogressionofage-related maculardegeneration,towetAMD.\nDoes my patient carry the genetic variations associated with vision loss when using chronic supplements\nsuch as AREDS?\n**Patients positive for VitaRisk are advised to avoid long-term AREDs/AREDS2 supplements",
    "Page_94": "Age-Related Degeneration Testing\nArctic Medical Laboratories (https://arcticdx.com)\nMaculaRisk\nPREDICTANDPROTECT\nMaculaRisk@is aDNA testcombining many of thegenes(15 geneticvariations in12genes)associatedwith the\nprogression of age-related macular degeneration(AMD).The geneticresult isintegrated into a formula\ndevelopedfromresearchatTuftsMedical Centerandincludesapatient'sage,AMD diseasestatus,height,\nweight,sex,age,andsmokinghistory.whichprovidesabasisforprogressionrisk\nWhat is the likelihood of my patient progressing to advanced AMD?\nShould my patient avoid chronic zinc supplementation?\n**Predictive algorithm touts 89% accuracy @ 2, 5 and 10-year time points",
    "Page_95": "Treatments for AMD\nG~Early detection and meaningful treatments with significant value, do not cure,\nbut all stages of AMD\n* Prescribe smoking cessation programs\n Smoking and AMD\nDepletes serum antioxidants\n Decreases pigmentary density\nIncreases risk to advanced AMD\n* Lifestyle changes\n Diet\n Exercise\n* Systemic disease management\n Cardiovascular disease, DM, obesity, high cholesterol",
    "Page_96": "Risk Alleles\nG~Ancestory\nG~23 and me\n6~Lot's of marketing once we they have the allele",
    "Page_97": "G~Nutritional supplements\nTreatment for AMD\n* Sub-clinical/sub-structural or early disease\n Controversy flourishes\n No definitive guideline exists\n Despite consensus evidence suggests using supplements\n* Intermediate - advance disease\n No controversy on advocating for supplements\n* AREDS1\n Contains Beta-carotene and no lutein or zeaxanthin, no longer recommended\n Investigated early AMD, no statistically significant benefit\n*AREDS2\n Recommended for intermediate and advanced AMD, study protocol\n★ The Practical Guide for the Treatment of AMD - 3 primary Options\n Macular pigment supplement\nCarotenoids:lutein, zeaxanthin, meso-zeaxanthin\n Carotenoids, antioxidants, zinc, and vitamins C & E\nAREDS2\n Carotenoid macular supplement in subclinical and early AMD. Carotenoid and antioxidant is\nintermediate and AMD that is progressing",
    "Page_98": "Treatment for AMD\nGRetinal light protection\n* Sun exposure\nG^Closer follow up\n* 12 months is currently accepted as being too long to defect progression\n* 6 months or sooner based on risk of CNV\nG~Low vision and rehabilitation consultation",
    "Page_99": "Oxidative Medicine\nandCellular Longevity\nOxid Med CellLongey.2019;2019:9783429.\nPMCID:PMC6390265\nPublished online 2019 Feb12.doi:10.1155/2019/9783429\nPMID:30891116\nHealth Benefits of Polyphenols and Carotenoids inAge-Related Eye\nDiseases\nSimona ungauMohamedMAbel-Daim2DliaMirelaTitEsraaGhanem4shimpei Sat\nMaikoMaruyama-lnoue,ShinYamane,andKazuakiKadonosono3\nAuthorinformationArticlenotesCopyright andLicense informationDisclaimer\nTreating Half the Retina?\nThis articlehasbeen cited by other articles in PMC.\nAbstract\nGoto:\nOxidative stressandinfammation playacriticalolein theinitiation and progressionofage-related ocular\nabnormalitis ascataract,glaucoma,diabeticretinopathy,andmacular egenerationhereore,\nphytochemicalswith proven antioxidant andanti-inflammatory activities,such ascarotenoids and\npolyphenols,could beof benefit in these diseases.WesearchedPubMedandWeb ofScience databasesfor\noriginal studiesinvestigating thebenefits ofdifferent carotenoids andpolyphenolsinage-related\nophthalmicdiseases.Ourresults showed that severalpolyphenols(such asanthocyanins,Ginkgo biloba,\nquercetin, and resveratrol and carotenoids such as lutein, zeaxanthin, andmezoxanthin) have show\nsignificant preventive and therapeuticbenefits against theaforementioned conditions.Theinvolved\nmechanismsin thesefindingsincludemitigating theproduction ofreactive oxygenspeciesnhibiting the\ntumornecrosisfactor-a andvascular endothelial growth factor pathways,suppressingp53-dependent\napoptosisand suppressing theproduction of inflammatorymarkers,suchasnterleukin(I）8,I6,I-\n1a,andendothelialleucocyteadhesionmolecule-1.Consumptionofproductscontaining these\nphytochemicalsmaybeprotectiveagainst these diseases;however,adequate human dataare lacking.This\nreviewdiscussestheroleandmechanismsof polyphenolsandcarotenoidsandtheirpossiblesynergistic\neffectsontheprevention andtreatmentof age-relatedeyediseasesthatareinducedoraugmentedby\noxidativestressandinflammation.",
    "Page_100": "Carotenoids and Polyphenols\nFurthermore,resveratrol maintains the vascular\nOncotarget,018,Vol.9,（No.24）pp:17181-17198\nfitnessthroughits antioxidant and anticoagulantactivities\nRevie\nOxidative stress: role of physical exercise and antioxidant\nand on the other hand is relevant inblocking the formation\nnutraceuticals in adulthood and aging\nofnew bloodvessels.in inhibiting the VEGFrelease\nCarolinaSimioniGiorgioZauli,AlbertoM.Marteli,MarcoVitale3,Giann\nand attenuating Hypoxia-Inducible Factor（HIF-la）in\nUniversityfBologna,Bolognataly\ndifferent tumor cells[163].\nesand Biotechnology,Phar\nary26.2018\nAcceped:March08.201\nCopyright\nASSESSMENTOFCAROTENOIDS\nResveratrol can be implied in anti-aging actions\nImpact of CarotenoidAssessment\nby influencing the mitochondrial environment and\nearchhasresulted in\nmetabolic diseases,\nattechniques.Thebreadthofpossibilitiesforas\nbyregulatingthelevels\nof\nent,and the\nsome inflammatory mediators and cytokinesand by\nmodulating lipolysis[125,152,153].Mitochondrial\ndysfunction has been proved to be associated with\naging and disease development[154],and it was seen\nThe\nofMP\nOncotarget\nmethodstyp",
    "Page_101": "Measuring Macular Pigment\nRetina macula biopsy\nClinical lmaging\nS\n*Subjective\n ZeaVision MPSII\n Guardion Mapcat SF\n*Clinical\n ZeaVision MPR\n Zeiss Visucam 200\n Spectralis HRA+OCT\n Spectralis MPOV\nThank you! Dr. Chris Putnam",
    "Page_102": "Measuring Macular Pigment\nG~Biophotonic Scanner\n40.000\n39.000\n* Measures carotenoids\n* Based on an optical method known as\nResonant Raman Spectroscopy (RsS)\n Used for many years in research laboratories\n60,000\n,000\n*Skin RRS measurements\n Noninvasive\n Objective\n Reliable methods to assess carotenoid levels\nOcular\nSystemic",
    "Page_103": "Carotenoid Levels\nOARVO\ncorrelates to blood\nBiomarker of health for\nClinical andEpidemiologicResearch\ndiet and lifestyle\nCorrelationsBetweenMacular,Skin,andSerum\nCarotenoids\nChristopherD.Conrady,JamesPBell,BrianM.Besch,Aruna Gorusupudi,Kelliann\n*Yale University\nFarnsworth,IgorErmakoy,²Mohsen Sharifzadeh,²Maia Ermakova,wernerGellermann,and\nPaul S.Bernstein\nntr,Salt Lake Ciy，Utah,Unitd Stat\nPhospholipid bi-layer\ny.UT\nG~Carotenoids, flavonoids.\n18,2017\nand polyphenols\n17-21818",
    "Page_104": "Carotenoid Levels\nHIN\nNational InstitutesofHealth\nTurningDiscovery IntoHealth\nQuick Test\n(approx. 30 sec)\nPortable\nCostEffective\nRemeasure in 60 days\nReassurance to you and patient",
    "Page_105": "Raman Spectroscopy\nCAROTENOID\nAROTENOIL\nEAROTENOI\n478nm PHOTONS ARE\nAS478nmPHOTONS STRIKE\nEMITTED FROM\nCAROTENOIDS IN THE SKIN, THEY\nTHE SCANNER\nARE REFLECTED BACK AS 518nm\nPHOTONS",
    "Page_106": "ResonanceRamanspectroscopicevaluationofskincarotenoids\nasabiomarkerofcarotenoidstatusforhumanstudies\nYale CENTER\nWernerGellermannd\nYaleSchoolofPublicHeathandYale Cancer Center,60\nCenterforScienceinthePublicInterest1220LStreet\nte300\nSA\nUSDA/ARS GrandForksHuman Nutrition Research Ce\n02ndAve\nhG\nSND58\nDepartmentofPhysicsandAstronomy.Universityof\nLakeCiry\nARTICLEINFO\nArtidle history:\nspectros\nnvasivemethodthathasbeendevelopedtoassesscarot-\nAvailableonlinexxx\nhumantissues\ndnskininvivo.Skincarotenoidstatushasbeensuggested as\napromisingbiomarkerforhumanstudies.This\nuiptdescribesresearchdonerelevanttothedevel-\nKeywords:\nopmentofthisbiomarker,including\niity.\nlidity,easibilityforuseinfedsettings,n\nCarotenoids\nfactorsthataffectthebi\nandadiposity.Recentstudieshaveevaluated\nSkin\notelioid interventionsbothsupplement-basedanddietary\nResonance Ramanspectroscopy\n[eg,provisiot\nItandvegetable（F/V)-enricheddiet],demonstratingconsistent\nBeta-carotene\nresponseto interv\ntid\nThe totalityof evidencesupports theuseof skincarotenoid statusasanobjec-\nBiomarker\ntivebiomarker\nVintake,althoughinthecross-sectionalsetting,dietexplainsonlysome ofthevar-\niationinthisbiomarker.However,thislimitationisalsoastrength inthatskincarotenoidsmay\nlack of smoking, and lack of adiposity. Thus, this biomarker holds promise as both a health biomarker\nand an objective indicator of F/V intake, supporting its further development and utilization for medical\nand public health purposes.\n*Arch Biochem Biophys. PMC 2014 Nov 15.",
    "Page_107": "ARVOSTUDY\nInterrelationships between Macula,Skin and Serum\nCarotenoids- Paul Bernstein,Werner Gellerman et al\nARVOMay2016\nConclusions:\n\"Our results emphasize the importance of\nmeasuringthetotalamountofcarotenoids\ninthemacularegionusinganobjective\nimage based modality such as AFl w\nSpectralis rather than subjective MPOD.'\nSkin resonance Raman Spectroscopy of skin\ncarotenoids is a reasonable biomarker of\nThe objective hand scanner is better than the subjective\nmacula carotenoid status. and correlates\nMacuscope, QuantifEYE, and Densitometer for estimating\nbetter than than subjective MPOD tests.\nmacula pigment.",
    "Page_108": "Vulnerable to Oxidation\nBetacarotene\nVitamin C\nLutein\nLycopene\nVitamin E",
    "Page_109": "53-year-old\nIman\n6~Family history of AMD\nCONGRATULATIONSONTAKINGTHEFIRSTSTEPS\n★ Dad with 43 injections for AMD\nTOWARDSOPTIMIZINGYOURSCS\nG~Pre-diabetic with borderline HbAlc\nDear\nG~Vision 20/20 OU\nRecently,on12/15/2020,youmetwithmeandscannedthepalmofyourhandwiththe\nBioPhotonicScanner.Your scanreturnedaSkin Carotenoid Score(SCs)of 26000.\nG~DFE- retina clear\nThisscorerepresentsthecurrentcarotenoidlevelofyourskinThehigherthescorethemore\ncarotenoidsyourbodyisreceiving.\nG~OCT normal\nG~Passes dark adaptation\n26000",
    "Page_110": "Calcium(asCalcium Carbonate,Di-CalciumMalate,\n250mg\n%6\nCalciumAscorbate)\nIngredients\nlodine(asPotassium lodide)\n50mcg\n33%\nMagnesium(asMagnesiumGlycinate,MagnesiumOxide)\n125mg\n30%\n%\nDaily\nZinc(asZincBisglycinate)\n7.5mg\n%89\nIngredients\nAmount\nValue\nSelenium(asL-Selenomethionine,SodiumSelenite)\n127%\nCopper(asCopperBisglycinate)\n0.5mg\nServing Size:1Packet\n56%\nVitaminA(83%asBetaCarotene(1875mcgRAE)from\nManganese(asManganeseBisglycinate)\n1mg\n43%\n2250\nBlakeslea trispora,andVitaminApalmitate)(375mcg\n250%\nChromium(asChromiumNicotinate Glycinate)\n100mcg\n286%\nmcgRAE\nRAE)\nMolybdenum(asMolybdenumBisglycinate)\n37.5mcg\n83%\nVitaminC(asCalciumAscorbate)\n200mg\n222%\nPolyphenolandFlavonoidBlend\n97.5mg\n5mcg\nVitaminD(asCholecalciferol)\n25%\nCatechins(fromCamellia sinensisLeafExtract)\n(45mg)\n(200IU)\nQuercetin\n(25mg)\nVitaminE(asD-Alpha-TocopherylAcetate,D-Alpha\n50.3mg\nGrapeSeedExtract(min.95%Polyphenols)\n(12.5mg)\n335%\nTocopherol,Tocotrienols)\nCitrusBioflavonoids(fromCitrusFruits)\n12.5mg)\nVitaminK(asPhytonadione)\n20mcg\n17%\nResveratrol(fromPolygonumcuspidatumrootextract)\n(2.5mg)\nThiamin(asThiamine Mononitrate)\n3.75mg\n313%\nMixedTovopherols(Gamma,Delta&BetaTocopherols)\n53mg\nRiboflavin(as Riboflavin)\n4.25mg\n327%\nAlpha-LipoicAcid\n15mg\n17.5mg\n109%\nnositol(as Inositol)\n5mg\nNiacin(asNiacinamide)\nNE\nCarotenoid Blend\n3.5mg\nVitaminB6(asPyridoxineHydrochloride)\n5mg\n294%\nycopene(asLycopene)\n(2.5mg)\n500mcg\nLutein(fromMarigoldFlowerExtract)\n(1mg)\nDFE\nFolate\n125%\n300mcg\nBoron(asBoron Citrate)\n1.5mg\nfolicacid)\nVanadium(asVanadyl Sulfate)\n10mcg\nVitaminB12(asCyanocobalamin)\n15mcg\n625%\nOTHERINGREDIENTS:Gelatin,MicrocrystallineCellulose,Crosmarmellose\n75mcg\nSodium,StearicAcid,MagnesiumStearate,SiliconDioxide,TitaniumDioxide\nBiotin(as Biotin)\n250%\nPantothenicAcid(asD-CalciumPantothenate)\n15mg\n300%\nCONTAINS:FishCod,Pollack,Haddock,Hake,Cusk,Redfish,Sole,Floundr)\nCalcium(asCalcium Carbonate,Di-CalciumMalate,\n250mg\n19%\nCalciumAscorbate)",
    "Page_111": "SUPPLEMENTFACTS\nSupplementFacts\nServing Size 2 Softgels\nServings Per Container80\nAmount Per Serving\n%V\nTotal Calaries\n15\nTotal Fat\n1g\n1%6*\nSaturated Fat\n09\n0%6*\nTransFat\n0g\nVitaminDa (as cholecalciferol)\n12.5 mcg (500 IU)\n63%\nVitamin K (as menaquinone-7)\n20 mcg\n17%\n1055mg\nUltra-pure fish oif concentrate:\nEPA (Eicosapentaenoic acid)\n300mg\n**\nDHA(Docosahexnenoic acid)\nCitrus Bioflavonoids\n100mg\n(including hesperidin and naringin)\nPurple corn Zea mays L) cpb exiract\n66.67 mg\nIncluding anthocyanins\nAlpha LipoicAcid\n50mg\nQuercetin(trom Dmorphandramos fruitextract)\n37.5mg\nD-Limonene(from Cirus sensis peel)\n25mg\nRosemary (Rosmarius officinalis L] leaf extract\n18.75 mg.\nincluding camosic acid\nResveratrol (from Polygonum cuspidatum root)\n15mg\nCoenzyme Q10\n15mg\n2.5mg\nLycopene\nLutein (fram marigold fiower (Targetes erectal)\n2mg\n++\nAstaxanthin (from Haematococcuspluvialis algae)\n0.5mg\nPercent Daily Values are based on a 2,000 CalorieDiet.\nDaily Value (DV) not established.\nOTHERINGREDIENTS:Gelatin,Glycerin,Beeswax,Sunflower Lecithin\nVanillin.\nCONTAINS:Fish(anchovies,sardines,mackerel).",
    "Page_112": "53-year-old\nman\nCONGRATULATIONSONTAKINGTHEFIRSTSTEPS\nCONGRATULATIONSONTAKINGTHEFIRSTSTEPS\nTOWARDSOPTIMIZINGYOURSCS\nTOWARDSOPTIMIZINGYOURSCS\nDear\nDea\nRecentlyon12/27/2020youmetwithmeandscannedthepalmofyourhandwiththe\nRecentlyon01/23/2021,youmetwithmeand1scannedthepalmofyourhandwiththe\nBioPhotonicScanner.Yourscanreturneda SkinCarotenoidScore(ScS）of33000.\nBioPhotonic Scanner.Your scan returnedaSkinCarotenoid Score(SCS)of47000.\nThisscorerepresentsthecurrentcarotenoidlevelofyourskin.Thehigherthescore,themore\nThisscorerepresentsthecurrentcarotenoidlevelofyourskinThehigherthescore,themore\ncarotenoidsyourbodyisreceiving.\ncarotenoidsyourbodyisreceiving\n33000\n47000",
    "Page_113": "Measuring\n Macular Pigment\nG~Retina macula biopsy\nG~Clinical Imaging\n* Subjective\n ZeaVision MPSIl\nGuardion Mapcat SF\n* Clinical\nZeaVision MPR\nZeiss Visucam 200\nSpectralis HRA+OCT\nSpectralis MPOV\nThank you! Dr. Chris Putnam",
    "Page_114": "Treatments for Choroidal Neovascularization (CNV)\nG~ Current Anti-VEGF treatments\n★ Bevacizumab (Avastin)\n Humanized full length monoclonal antibody\nAMD\n★ Ranibizumab (Lucentis)\n Humanized monoclonal antibody fragment\n AMD, DME, DR, RVO\n* Aflibercept (Eylea)\n Fusion protein\n AMD, DME, DR\n★ brolucizumab-dbll (Beovu)\n Humanized single-chain antibody fragment\n Up to 3 months dosing intervals, most are 4-6 weeks\n50% remained 3 months after 1 year\n★ Pegaptanib (Macugen)\n RNA aptamer\n AMD",
    "Page_115": "foDsonFacebook\nthan going in.Tough call.\n?\nODs on Facebook\nLike·Reply-1d\nDr.Alan Glazier\n3,425like this\nLoss of fovealp\nSend Message\nogroup\nmay be vitellfor\nGreg CaldwellChad,great case topresent.Regarding the\ncataracts ou.w\nAbout\nERMI agree with my colleagues about monitor.Iagree this does\nUNITS\nGo to Units\nDiscussion\nnotneed toseeretinabasedon theERMand drusen.Iamgoing\n0of 2required unitscompleted\nAnno\ntorespectfully disagree about justmonitoring these drusen and\nMembers\nthispatient.I will startoff by saying thereareonly4OCTsto\nUnits areawayfor groupadminsto share\nEvents\nreview,lookingatmorewould help supportmythoughts,butthe\nknowledgeandresourceswithyou.\ntwo here are enough forme to weigh in.TheOCTs on the left\n11\nVideos\nPhotos\nsidetop and bottom are showing signs of progression and that\nINVITE MEMBERS\non'tforgetmacularfield\nthe RPE is sicker than just monitor.At the topof these drusen are\nFiles\nhyper-reflective foci a sign of progression.In the top left OCT1\n02\n39,870Members\nsee two columns of sub-RPE hyper-reflective columns and the\nnless VA is at least 20/40.\nWatchParty\nbottom left 5-6 columns.The RPEabsorbs the OCT (coherent)\nlight typicallykeeping the choroid black.Thesehyper-reflective\nSearch this group\nQ\nDESCRIPTION\nrasfienthan\nCreateOroup\ncolumns are likerays of sunlightpoking through on a cloudy day.\nemuntil20/40orwo\norse.lf\nThiscommunityiPRIVATE.Ds,stdents\nowwould you like todo\nnates.\nThe RPE is atrophied here and the OCT coherent light ismaking\nOpticians,Industry/Op.SeeMore\nemseethe sameor worse\nCCT Connect\nGROUPTYPE\nGceAll\nitswayinto the choroid.This RPEis sicker thanyou think,its\n?1\nSocial Leaning\noxidized,inflamed,it‘s sick.Rather thanmonitorbased upon\ner\nODs on Facebook\nhyper-reflective foci and sub-RPEhyper-reflective columnsI\npresent.Regarding the\nCREATENEWGROUPS\n2020-March15\nDrs.Centar.mlerGjur\nwouldtreatthispatient.Treatmentwouldbetostopsmokingif\nGroups makeiteasier than\nsedrucongo\nevertosharewithfriends,\nCreateGroup\nModical OptometryA.\nthe patientisasmoker,discusshis/herdietand exercise,discuss\nfamily and teammates.\nCME40D\nthe best possible management for his/her (systemic health) DM,\nportemythough\nSteelrs Nation\n20+\ncholesterol, obesity,cardiovascular, as these are all risk factors\nBrianGe\nUPCOMING GROUP EVENTS\nSeeAll\nOptometrists of Am\nLike Rep\ninAMD.Sunglasses in any ultraviolet light.Prescribe nutritional\nssion.nthetoplftOCT\n31stAnnual Ocular\n020\nPOA ODson Facebok\nsupplements,this RPEis sick enough torecommend AREDS2,if\neflective columns and the\nTracy Ki\nyou want to avoid the high zinc levels then do something with 25\nthehyper-ref\nLike-Rep\nCiboleS\nmg of zinc, or at least triple carotenoid therapy (lutein,\nCancun Mexico\nWalt Disney Word A\nzeaxanthin,and meso-zeaxanthin).These OCTswith the drusen\nsickerthanyouthink,its\nLike-Rep\nCreated for ODs on\nManaged Mediceid in \nFacebook\nStevoBu\nadvanced AMDwhich is geographic atrophy and/or CNV.Julie\nEyenis CD's\nLike-Rep\nerdietand exercise,discus\nFriedman Rodman any othercomments?Alan Glazier this would\ns/her(systemic health) DM,\nCEin Italy/Europe Bava\nDavis Vislon Optic20\nDr.Alan\nbeagreat case topresent when we share the podium again on\n26\nApril26,2020-April28\ncasesfrom ODson FB.Respectfully,Greg\n2020\nHeidelberg Germany\nLike·Reply·2m\nJamesFanelli invitedyou to\nanevent for ODson\npophyan\nFacebooko\nWrite a comment...\nGreg",
    "Page_116": "Resource:\n: OCT Community for OCT and OCTA\nOCT\nCONNECT\nPost your questions & cases so we can #OCTConnect!\nJoin this group to become part of our\nOCT ConnectFamily!",
    "Page_117": "Book Resources\nOptical Coherence\nTomographyAngiography\nAtlas:A Case StudyApproach\nJulieARodman,ODMScFAA\nOptical CoherenceTomography\nAngiography Atlas:\nACase StudyApproach\nATLAS of\nRETINALOCT\nDarin R.Goldman\n$149.95\nNadia K.Waheed\nISBN101-63091-641-2\nJay S. Duker\nISBN13978-1-63091-641-1\n200ppHard Cover\nELSEVIER\nPub,Date:2019\nOrder#66411",
    "Page_118": "AMD A-to-OCT-to-Rl-to-Z\nWhat You Need to Know\nThank You!!!\nHope You Enjoyed!\ngrubod@gmail.com\n814-931-2030"
}